Radical cystectomy (RC) is the primary treatment strategy for patients with muscular invasive bladder cancer (MIBC). However, the prognosis is poor and tumor recurrence is not rare, in particular, urethral recurrence (UR) in male patients who underwent RC combined with urinary diversion.
Radical cystectomy is a complex surgery with a high rate of complications including infections, which lead to increased morbidity and mortality, longer hospital stay and higher costs. The aim of this work is to evaluate health care-associated infections (HAIs) in these patients, as well as associated microorganisms, antibiotic resistance profiles and risk factors.
<i>Background:</i> We describe the oncological and functional outcomes and the surgical technique of the photodynamic diagnosis (PDD)-assisted en bloc transurethral resection of bladder tumor (TURBT) using a rectangular cutting loop.
Upper tract urothelial carcinoma (UTUC) accounts for roughly 5% of urothelial carcinomas. Historically, the gold standard for high-risk or bulky low-risk UTUC was an open radical nephroureterectomy with formal bladder cuff excision (BCE).
Radical cystectomy is standard of care and part of a multidisciplinary approach for long-term survival in patients with muscle-invasive bladder cancer (MIBC) or high-grade non-MIBC. Recent data have suggested that anesthetic technique can affect long-term survival and recurrence in patients undergoing cancer related surgery.
After the outbreak of COVID-19 unprecedented changes in the healthcare systems worldwide were necessary resulting in a reduction of urological capacities with postponements of consultations and surgeries.
Sentinel node (SN) biopsy in penile cancer (PeCa) is typically performed using 99mTc-nanocolloid and blue dye. Recent reports suggested that the hybrid (radioactive and fluorescent) tracer indocyanine green (ICG)-99mTc-nanocolloid may improve intraoperative optical SN identification.
(UroToday.com) The randomized phase 3 ALSYMPCA trial1 demonstrated an improvement in overall survival and symptomatic skeletal events for the treatment of metastatic castration-resistant prostate cancer (mCRPC) using the alpha-emitter radium-223 in patients with 2+ bony metastases, no visceral metastases, and metastatic lymph nodes < 3 cm in size. The optimal sequencing of radium-223 (Ra-223), especially in […]
(UroToday.com) Though patients with non-metastatic castration-resistant prostate cancer (nmCRPC) are generally asymptomatic from their cancer, the development of metastatic disease reduces their quality of life for several reasons. Three drugs that target the androgen receptor are approved in nmCRPC and delay time to the development of metastatic disease. However, treatment with these agents is associated with […]
(UroToday.com) Though the clinical trials leading to approval of life-prolonging therapies in metastatic castrations resistant prostate cancer (mCRPC) included a substantial minority of patients over the age of 75, the efficacy and impact on the quality of life in more senior patients is not clearly established. To gather more information on this question, the authors […]
